Applied Biosystems to Acquire the Research Products Division of Ambion, Inc.
Applied Biosystems Group, an Applera Corporation business, and Ambion, Inc. announced they have signed a definitive agreement whereby Applied Biosystems will acquire the Research Products Division of Ambion, a premium supplier of RNA-based reagents for life science research and drug development, for approximately $273 million in cash. The transaction is subject to regulatory and other customary closing conditions and is expected to close in the first calendar quarter of 2006.
Other news from the department business & finance
These products might interest you

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection

Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines

CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy

Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Breakthrough at Ark opens way to reduce side-effects and increase efficacy of anti-cancer therapies - Unique DNA-based targeting technology Scavidin halts tumour progression with one-tenth of conventional chemotherapy dose
BioFocus and Almac collaborate to offer fluorescent lifetime assays
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
